Abstract
Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.
Keywords: platelet activation, endothelial activation, target organ damage, Hypertension
Current Pharmaceutical Design
Title: Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy
Volume: 12 Issue: 13
Author(s): Sunil K. Nadar, Muzahir H. Tayebjee, Franz Messerli and Gregory Y.H. Lip
Affiliation:
Keywords: platelet activation, endothelial activation, target organ damage, Hypertension
Abstract: Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.
Export Options
About this article
Cite this article as:
Nadar K. Sunil, Tayebjee H. Muzahir, Messerli Franz and Lip Y.H. Gregory, Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy, Current Pharmaceutical Design 2006; 12 (13) . https://dx.doi.org/10.2174/138161206776843368
DOI https://dx.doi.org/10.2174/138161206776843368 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular and Physiological Effects of Soy Flavonoids
Mini-Reviews in Medicinal Chemistry An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Sleep Apnea and Coronary Heart Disease: From Dusk Till Dawn and Further
Current Respiratory Medicine Reviews Cyclic ADP-ribose (cADPR) and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP): Novel Regulators of Ca 2+-Signaling and Cell Function
Current Molecular Medicine Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets New Aspects in Sustained Drug Release Formulations
Recent Patents on Drug Delivery & Formulation Henoch-Schönlein Purpura in Children: An Updated Review
Current Pediatric Reviews Subject Index To Volume 3
Current Neurovascular Research High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Current Pharmaceutical Analysis Effects of Senna didymobotrya Root Extract and Compounds on Tritoninduced Hyperlipidaemic Rats and Differentiation of 3T3-Li Preadipocytes
The Natural Products Journal The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery Advance in Understanding the Biosynthesis of Prostacyclin and Thromboxane A2 in the Endoplasmic Reticulum Membrane via the Cyclooxygenase Pathway
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: “Amniotic Fluid Embolism: Novel Biomarkers for Future Diagnostic Investigation and Therapy”)
Current Pharmaceutical Biotechnology Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus: The Era of Novel Anti-diabetic Agents
Current Medicinal Chemistry Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Myocardial Energetics in Left Ventricular Hypertrophy
Current Cardiology Reviews Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology